Clinical Supply Manufacturing Articles
-
EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence?
6/19/2025
The EMA’s Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials came into effect on July 1, 2025
-
Multiplying Forces Of Clinical Supply Outsourcing
1/30/2023
There are a number of varying and converging forces baring down on sponsors looking for CROs/CDMOs who can provide a full slate of services around their clinical-trial material. Both CDMOs and sponsors need to add or subtract from their strategies to adjust.
-
Peeling Back The Layers Of Radiolabeled Peptide Production
6/12/2025
From the moment radiolabeled drugs are made, it’s a race to get them to patients. Radioactive decay is just one of many complications. Here’s one company’s approach.
-
Challenges And Opportunities Of Outsourcing Biopharma Development
2/19/2025
Oversight, knowledge management, and operational/compliance risk make up the three key challenge classifications to consider when approaching a new outsourcing agreement.
-
Drug Product Formulation & Process Development: The Must-Have Skills At A Glance
8/26/2024
Specialists in drug product formulation and process development at small biopharmas need to balance scientific knowledge and multidisciplinary know-how across the stages of product development.
-
Inside Arbor Biotech's In Vivo Gene Therapy Approach
8/6/2025
Following recent news about first-in-human testing, two executives discuss the science and manufacturing strategy for the company's lead candidate, ABO-101.
-
Green Gains In Biopharma Without Closing Facilities?
2/29/2024
Going green is virtually impossible for biopharma companies with legacy systems, but going greener might be within reach. Here are some ideas to get started.
-
New DSCSA Compliance Blueprint Includes FDA & Industry Input
4/12/2023
Pharmaceutical manufacturers, distributors, and pharmacies must all ensure they are ready for the Drug Supply Chain Security Act (DSCSA)'s full implementation starting on Nov. 27, 2023. The Partnership for DSCSA Governance, a public-private partnership, has published a blueprint compiling input from every sector, including FDA, industry, and solution providers.
-
What's In The Leukopak Matters For Cell Therapy Manufacturing
10/11/2024
Advanced cell-based therapies are impossible without high-quality leukopaks from high-quality donors.
-
Scaling RNA Production From The Lab To The Clinic
8/9/2024
Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics.